Perspectives of caregivers of older adults with acute myeloid leukemia during initial hypomethylating agents and venetoclax chemotherapy

BACKGROUND: Older adults with AML commonly receive a hypomethylating agent (HMA) as first-line therapy. The addition of venetoclax (VEN) to HMAs has been shown to improve remission rates and overall survival. The use of combination therapy (HMA + VEN) requires frequent follow-up, results in longer i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Kelly R., Chan, Ya-Ning, Iadonisi, Katie, Poor, Elissa, Betancur, Stephanie, Jung, Ahrang, Sagester, Kathryn, Coppola, Susan, Pergolotti, Mackenzi, Kent, Erin E., Schwartz, Todd, Richardson, Daniel, Bryant, Ashley Leak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811045/
https://www.ncbi.nlm.nih.gov/pubmed/36598590
http://dx.doi.org/10.1007/s00520-022-07565-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811045/
https://www.ncbi.nlm.nih.gov/pubmed/36598590
http://dx.doi.org/10.1007/s00520-022-07565-7

Ejemplares similares